Dr. Silverman is the founder and CEO of Revere Pharmaceuticals, an oncology-focused biotech company based in Boston. Prior to Revere, he was the General Counsel of Concert Pharmaceuticals from 2007 to 2017, helping the company become public in 2014. He currently serves as an advisor for Concert and on the advisory board for Larmor Biosystems. Previously, Dr. Silverman was Associate General Counsel at Millennium Pharmaceuticals (now Takeda) where he led the company’s chemical patent practice. Prior to Millennium, he served in various legal roles at Vertex Pharmaceuticals and FMC Corporation. Dr. Silverman started his career as a research chemist. He has over 20 US patents. Dr. Silverman received his BA degree from Lehigh University, his PhD from the U of New Mexico and did post-doctoral training in organic chemistry at Stanford University. He received his JD from Rutgers Law School.